



# Richard Francis

Incoming President & Chief Executive Officer,  
Effective January 1, 2023

## Compelling Track Record of Growing Businesses

- 2021 – PRESENT
  - Serves as CEO of Syncona portfolio company Purespring Therapeutics, one of the first AAV gene therapy companies focused on the kidney globally
    - Serves as CEO of Syncona portfolio company Forcefield Therapeutics, a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes
- 2014 – 2019
  - Served as CEO of Sandoz and as a member of the Novartis Executive Team
    - Developed transformative strategy to reshape the business by focusing organization on key geographies, reshaping the portfolio and targeting efficiencies to drive growth and margin improvement
- 2001 – 2014
  - Held a number of senior roles at Biogen, including leading the U.S. business
    - Oversaw the growth of the U.S. Commercial business, driven by a strategic focus on commercial excellence and led the successful launch of Tecfidera® in 2013

## Education

- BA in Economics, The Manchester Metropolitan University

## Ideal Leader for Next Phase in Teva's Exciting Journey

- Over two and a half decades of pharmaceutical experience
- An entrepreneurial and pragmatic leadership style
- Right leader to further our mission and continue driving value creation for patients, employees, shareholders, and other stakeholders



I have long been impressed with the value Teva provides to patients globally and I am honored to take on the role of leading this extraordinary company into the future. I look forward to leveraging my background and years of pharmaceutical experience to build on Teva's strong fundamentals and to write the next exciting chapter for Teva, focusing on building a solid pathway to deliver long-term growth. I continue to see a bright future ahead for the Company and look forward to working closely with the Board, management team and talented employees to continue driving value creation for patients, employees, shareholders, and other stakeholders."

— RICHARD FRANCIS